Study for the Use of Alteplase in Patients Who Awaken With Stroke

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a pilot study of thrombolytic therapy in patients with ischemic stroke who present with stroke symptoms upon awakening.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Diego
• Collaborators: National Institute of Neurological Disorders and Stroke (NINDS); Scripps Health
• Treatments: Tissue Plasminogen Activator

Criteria

Inclusion Criteria:

1. Age ≥22

2. Stroke upon awakening

3. Measurable deficit by NIHSS

4. No deficit before sleep or last seen normal before to sleep

5. Head CT with no evidence of intracranial hemorrhage.

6. Able to receive IV t-PA treatment within 2.5 hrs after patient awoke with deficit.

7. Written informed consent signed and dated by the patient (or patient's authorized representative)

8. Core lesion: ASPECTS ≥7 on MRI-DWI, CTP-CBV or CTA source imaging.

9. Mismatch of at least 20% measured by CT CVB/MMT or DWI/TTP

Exclusion Criteria:

1. Stroke or serious head trauma within the preceding 3 months

2. Major surgery or serious trauma within 14 days

3. History of intracranial hemorrhage

4. Systolic blood pressure above 185 mm Hg or diastolic blood pressure above 110 mm Hg that is not controlled after aggressive measures.

5. Rapidly improving or minor symptoms

6. Symptoms suggestive of subarachnoid hemorrhage.

7. Gastrointestinal hemorrhage or urinary tract hemorrhage within the previous 21 days.

8. Arterial puncture at a non-compressible site within the previous 7 days

9. Seizure at the onset of stroke and considered the cause for the neurological symptom.

10. Patients who are taking anticoagulants or who had received heparin within the 48 hours preceding the onset of stroke and have an elevated partial-thromboplastin time, INR>1.7 or platelet counts below 100,000/mm3

11. Finger sticks glucose below 50 mg/dl (2.7 mmol/ Lt) or above 400 mg per deciliter (22.2 mmol/Lt) and considered the cause for the neurological symptom.

12. Active internal bleeding

13. Pregnancy in women of child-bearing potential (must have pregnancy test, urine or blood, prior to therapy).

14. Lumbar puncture within 7 days.

15. Known co-morbid conditions likely to complicate therapy or interfere with patient assessment, such us: heart failure stage 4, severe dementia, end-stage AIDS, pericarditis, cirrhosis or known cancer.

16. Unable to obtain CTA or perfusion brain studies (PWI or CTP)